Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly carboplatin plus AZD1775 dose-escalation study in p53-mutated solid tumors
NL-OMON45937Phase 1Withdrawn
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adavosertib and carboplatin in Nonhematologic neoplasms, ovarian cancer, non-small cell lung cancer (NSCLC) and 3 more, sponsored by Netherlands Cancer Institute. Primary endpoint: Maximum tolerated dose. Planned start Jul 2018; status: withdrawn.
02
Drugs
adavosertibcarboplatin
03
Conditions
Nonhematologic neoplasmsovarian cancernon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NL-OMON45937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45937.